Improvements in Cardiovascular Risk Management Needed for MPN
June 11th 2021Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.
Rituximab Maintenance Improves Time-to-Next Treatment and OS in Patients With Mantle Cell Lymphoma
June 11th 2021Time-to-next treatment and overall survival were improved in a real-world study evaluating patients who received rituximab maintenance after first-line treatment with bendamustine and rituximab or R-CHOP in patients with mantle cell lymphoma.
The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.
Zanubrutinib May Be Superior to Ibrutinib in Relapsed/Refractory CLL/SLL
June 11th 2021Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zandelisib/Zanubrutinib Yields Promising Responses in R/R CLL, and B-cell Malignancies
June 11th 2021A 60 mg dose of zandelisib administered on an intermittent schedule from cycle 1 plus 80 mg of zanubrutinib twice daily yielded promising response rates in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.
Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma
June 14th 2020The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Mild COVID-19 Symptoms Are Associated with Poorer Outcomes in Sickle Cell Disease
Results from a survey of patients in the United Kingdom showed patients with sickle cell disease diagnosed with COVID-19 and who had mild symptoms were more likely to die or require mechanical ventilation than those with more severe symptoms of COVID-19.
Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera
More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.
Luspatercept-aamt Reduces RBC Transfusion Burden in Patients With Rare Blood Disorder
Data from the BELIEVE trial showed that luspatercept-aamt, a first-in-class erythroid maturation agent designed to regulate late-stage red blood cell maturation, reduced the need for red blood cell transfusions across every subgroup of patients with beta-thalassemia.